Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SUVN-I6107 In Healthy Participants

Phase 1

Recruiting

• Conditions: Healthy
• Interventions: Drug: SUVN-I6107; Drug: Placebo

• Registration Number: NCT06705088
• Lead Sponsor: Suven Life Sciences Limited

Brief Summary

The purpose of this study is 1) to investigate how safe and tolerable SUVN-I6107 is after a single oral dose at increasing dose levels and multiple oral doses at increasing dose levels, 2) to determine the pharmacokinetic (PK) profile after single and multiple ascending oral doses, 3) to investigate the effects of food on SUVN-I6107 pharmacokinetics and 4) to evaluate the pharmacodynamic (PD) effects of single and multiple ascending oral doses of SUVN-I6107 on quantitative electroencephalogram (qEEG) and event-related potential (ERP) assessments.

Detailed Description

This research study is a randomized, single-center, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD), first-in-human study in healthy participants.

This study consist of 2 segments: Segment 1 will be the SAD portion and Segment 2 will be the MAD portion.

Segment 1 will include up to 5 sequential cohorts. Up to 40 healthy male or female subjects, ages 18 - 45 years (inclusive) old at screening will be enrolled.

Segment 2 will include up to 3 sequential cohorts. The dosing will be administered for 14 consecutive days. Up to 24 healthy male or female subjects, ages 50 to 80 years (inclusive) old at screening will be enrolled.

Study Timeline

• Study First Submitted: 2024-11-14
• Study First Submitted QC: 2024-11-25
• Study First Posted: 2024-11-26
• Status Verified: 2025-01
• Study Start: 2025-01-07
• Last Update Submitted: 2025-01-08
• Last Update Posted: 2025-01-09
• Primary Completion: 2025-10-13
• Study Completion: 2025-10-13

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

• Body mass index (BMI): 18.0 to 30.0 kg/m2 for Segment 1 and 18.0 to 32.0 kg/m2 for Segment 2, inclusive, at screening and weight at least 50 kg and no more than 100 kg.
• Ability and willingness to abstain from alcohol-, caffeine-, and methylxanthine-containing beverages or food (eg, coffee, tea, cola, chocolate, energy drinks) from 48 hours (2 days) prior to each admission to the clinical facility until study discharge.
• All values for hematology and clinical chemistry tests of blood and urine within the normal range or showing no clinically relevant deviations, as judged by the Investigator, at screening and at admission.

Exclusion Criteria

• Females who are pregnant, lactating, planning to become pregnant, or planning to donate ova/oocytes during this study or within 30 days after last administration of study drug.
• Males with female partners who are pregnant, lactating, or planning to become pregnant during this study or within 90 days after dosing of study drug.
• Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of admission to the clinical site.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Single Ascending Dose	SUVN-I6107	single ascending doses administered orally
Single Ascending Dose	Placebo	single ascending doses administered orally
Multiple Ascending Dose	SUVN-I6107	multiple ascending doses administered orally for 14 days.
Multiple Ascending Dose	Placebo	multiple ascending doses administered orally for 14 days.

Primary Outcome Measures

Name	Time	Method
Number of participants with treatment-related adverse events	From Day 1 to Day 11 (Segment 1) and from Day 1 to Day 24 (Segment 2)	Number of participants with adverse events (AE), discontinuations due to AE or serious adverse event \[SAE\], and withdrawals from the study due to AE.
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Values	From Baseline to Day 11 (Segment 1) and to Day 24 (Segment 2)	Descriptive statistics of QTcF for observed values and changes from baseline will be summarized at each scheduled time point.
Number of Participants With Clinically Significant Changes in Blood Pressure	From baseline to Day 11 (Segment 1) and to Day 24 (Segment 2)
Number of Participants With Clinically Significant Changes in Pulse Rate	From baseline to Day 11 (Segment 1) and to Day 24 (Segment 2)
Number of Participants With Clinically Significant Changes in Body Temperature	From baseline to Day 11 (Segment 1) and to Day 24 (Segment 2)
Number of Participants With Clinically Significant Changes in Respiration Rate	From baseline to Day 11 (Segment 1) and to Day 24 (Segment 2)
Changes in Columbia Suicide Severity Rating Scale (C-SSRS) Score	From baseline to Day 24 (Segment 2)	The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk.

Secondary Outcome Measures

Name	Time	Method
Area under the concentration-time curve (AUC)	Day 1 and Day 14	SUVN-I6107 concentrations levels will be assessed after single and multiple ascending oral doses.
Maximum observed concentration (Cmax)	Day 1 and Day 14	SUVN-I6107 maximum observed concentration will be assessed after single and multiple ascending oral doses.
Time to reach maximum concentration (Tmax)	Day 1 and Day 14	Time to reach maximum concentration will be assessed after single and multiple ascending oral doses.
Terminal half-life (t½)	Day 1 and Day 14	SUVN-I6107 elimination rate will be assessed after single and multiple ascending oral doses.

Trial Locations

Locations (1)

Clinical Research Site; 🇺🇸 San Antonio, Texas, United States